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 We have read with interest the letter from Urrego et al regarding clinical and methodological 
concerns related to the Cancer-DACUS
1
.  
Authors question about the fact that patients, at the time of randomization, may not have a “truly 
active cancer”. We have to highlight that enrolled patients were included in the study after 6 months 
of treatment with Low Molecular Weight Heparin (pre-study period). Therefore, we cannot exclude 
that more aggressive tumors have determined deaths during this period; indeed, approximately 20% 
of patients, originally screened for inclusion in the Cancer-DACUS, died during the pre-study 
period. 
On the other hand we do not agree that tumor-related thrombophilia was low in our cohort, since the 
rate of recurrence in patients in Group A2 , with the highest expected risk for recurrent Deep Vein 
Thrombosis (having residual vein thrombosis not randomized to treatment with LMWH), was high 
as 22 %, even more than expected
2,3 
.  
With reference to the second comment, related to the time to recurrent Venous Thromboembolism 
(VTE), in Figure 3 we have reported for each defined time point (six, twelve and eighteen months, 
respectively) after randomization, the total amount of patients that developed recurrent VTE for 
each group
1
. Kaplan Meier analysis was performed and initially included in the paper but further 
revisions of the manuscript considered it as not critical for the aim of the study.  
Lastly, we agree with authors on the opportunity of prolonged treatment with LMWH in patients 
with active cancer; we also believe in the benefits of this approach in the prevention of recurrences 
but further extended ad hoc studies are needed.  
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